Episodic Cluster Headache Clinical Trial
Official title:
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache
Verified date | June 2011 |
Source | Winston Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).
Status | Completed |
Enrollment | 2 |
Est. completion date | January 2004 |
Est. primary completion date | January 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
- At least 2 year history of episodic cluster headache (meeting IHS criteria) - At least 2 previous episodes - Expected duration of cluster period is at least 6 weeks but not longer than 24 weeks - At least 1 but not more than 8 headaches on each of the 3 days immediately prior to treatment |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Diamond Headache Clinic | Chicago | Illinois |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Colorado Neurology and Headache Clinic | Denver | Colorado |
United States | New York Headache Center | New York | New York |
United States | San Francisco Clinical Research Center | San Francisco | California |
United States | California Medical Clinic for Headache | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
Winston Laboratories |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01341548 -
Civamide Nasal Solution for Cluster Headache
|
Phase 3 | |
Terminated |
NCT02209155 -
R-Verapamil for the Prophylaxis of Episodic Cluster Headache
|
Phase 2 | |
Unknown status |
NCT00399243 -
Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache
|
Phase 4 | |
Completed |
NCT02397473 -
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
|
Phase 3 | |
Completed |
NCT02797951 -
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
|
Phase 3 | |
Completed |
NCT00033839 -
A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache
|
Phase 3 | |
Terminated |
NCT02945046 -
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
|
Phase 3 |